MAP2K1 and neoplasm: The high-risk group demonstrated an increased sensitivity to BMS-536924, an IGF-1R inhibitor that targets tumor growth and survival pathways [32]; SCH772984, an ERK1/2 inhibitor that disrupts cell proliferation and progression via the MAPK pathway [33]; and Selumetinib, a MEK1/2 inhibitor that blocks a critical signaling cascade involved in tumor cell survival [34].